8-K 1 b39726bie8-k.txt BIOGEN, INC. 1 Securities and Exchange Commission Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 12, 2001 Biogen, Inc. (Exact name of Registrant as specified in its charter) Massachusetts 0-12042 04-3002117 -------------- ------------ ------------------- (State or other (Commission (IRS Employer jurisdiction of File Number) Identification No.) incorporation) 14 Cambridge Center Cambridge, MA 02142 (Address of principal executive offices) (Zip Code) Registrant's telephone number, including area code: (617) 679-2000 2 ITEM 5. OTHER EVENTS. On June 12, 2001, the Registrant publicly disseminated a press release announcing the results of two Phase III clinical trials of its AMEVIVE(TM) (alefacept) product. The information contained in the press release is incorporated herein by reference and filed as Exhibit 99.1 hereto. ITEM 7. FINANCIAL STATEMENTS AND EXHIBITS. (c) Exhibits. 99.1 The Registrant's Press Release dated June 12, 2001. 3 SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. BIOGEN, INC. By: /s/ Thomas J. Bucknum ---------------------------------- Thomas J. Bucknum Vice President - General Counsel Date: June 14, 2001 4 EXHIBIT INDEX Exhibit Number Description ------ ----------- 99.1 The Registrant's Press Release dated June 12, 2001